-
BMC Medicine Aug 2020An effective vaccine against Bordetella pertussis was introduced into the Expanded Programme on Immunisation (EPI) by WHO in 1974, leading to a substantial global... (Meta-Analysis)
Meta-Analysis
The burden of laboratory-confirmed pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunisation (EPI) in 1974: a systematic review and meta-analysis.
BACKGROUND
An effective vaccine against Bordetella pertussis was introduced into the Expanded Programme on Immunisation (EPI) by WHO in 1974, leading to a substantial global reduction in pertussis morbidity and mortality. In low- and middle-income countries (LMICs), however, the epidemiology of pertussis remains largely unknown. This impacts negatively on pertussis control strategies in these countries. This study aimed to systematically and comprehensively review published literature on the burden of laboratory-confirmed pertussis in LMICs over the 45 years of EPI.
METHODS
Electronic databases were searched for relevant literature (1974 to December 2018) using common and MeSH terms for pertussis. Studies using PCR, culture or paired serology to confirm Bordetella pertussis and parapertussis in symptomatic individuals were included if they had clearly defined numerators and denominators to determine prevalence and mortality rates.
RESULTS
Eighty-two studies (49,167 participants) made the inclusion criteria. All six WHO regions were represented with most of the studies published after 2010 and involving mainly upper middle-income countries (n = 63; 77%). PCR was the main diagnostic test after the year 2000. The overall median point prevalence of PCR-confirmed Bordetella pertussis was 11% (interquartile range (IQR), 5-27%), while culture-confirmed was 3% (IQR 1-9%) and paired serology a median of 17% (IQR 3-23%) over the period. On average, culture underestimated prevalence by 85% (RR = 0.15, 95% CI, 0.10-0.22) compared to PCR in the same studies. Risk of pertussis increased with HIV exposure [RR, 1.4 (95% CI, 1.0-2.0)] and infection [RR, 2.4 (95% CI, 1.1-5.1)]. HIV infection and exposure were also related to higher pertussis incidences, higher rates of hospitalisation and pertussis-related deaths. Pertussis mortality and case fatality rates were 0.8% (95% CI, 0.4-1.4%) and 6.5% (95% CI, 4.0-9.5%), respectively. Most deaths occurred in infants less than 6 months of age.
CONCLUSIONS
Despite the widespread use of pertussis vaccines, the prevalence of pertussis remains high in LMIC over the last three decades. There is a need to increase access to PCR-based diagnostic confirmation in order to improve surveillance. Disease control measures in LMICs must take into account the persistent significant infant mortality and increased disease burden associated with HIV infection and exposure.
Topics: Bordetella pertussis; Developing Countries; Female; History, 20th Century; Humans; Immunization Programs; Male; Whooping Cough
PubMed: 32854714
DOI: 10.1186/s12916-020-01699-3 -
Frontiers in Cell and Developmental... 2020Ovarian insufficiency is identified as a perplexing entity in the long list of pathologies impairing fertility dynamics. The three distinct classifications of ovarian...
Reporting on the Role of miRNAs and Affected Pathways on the Molecular Backbone of Ovarian Insufficiency: A Systematic Review and Critical Analysis Mapping of Future Research.
Ovarian insufficiency is identified as a perplexing entity in the long list of pathologies impairing fertility dynamics. The three distinct classifications of ovarian insufficiency are poor ovarian response, premature ovarian insufficiency/failure, and advanced maternal age, sharing the common denominator of deteriorated ovarian reserve. Despite efforts to define clear lines among the three, the vast heterogeneity and overlap of clinical characteristics renders their diagnosis and management challenging. Lack of a consensus has prompted an empirically based management coupled by uncertainty from the clinicians' perspective. Profiling of patients in the era of precision medicine seems to be the way forward, while the necessity for a novel approach is underlined. Implicating miRNAs in the quest for patient profiling is promising in light of their fundamental role in cellular and gene expression regulation. To this end, the current study sets out to explore and compare the three pathophysiologies-from a molecular point of view-in order to enable profiling of patients in the context of fertilization treatment and enrich the data required to practice individualized medicine. Following a systematic investigation of literature, data referring to miRNAs were collected for each patient category based on five included studies. miRNA-target pairs were retrieved from the DIANA-TarBase repository and microT-CDS. Gene and miRNA annotations were derived from Ensembl and miRbase. A subsequent gene-set enrichment analysis of miRNA targets was performed for each category separately. A literature review on the most crucial of the detected pathways was performed to reveal their relevance to fertility deterioration. Results supported that all three pathophysiologies share a common ground regarding the affected pathways, naturally attributed to the common denominator of ovarian insufficiency. As evidenced, miRNAs could be employed to explore the fine lines and diverse nature of pathophysiology since they constitute invaluable biomarkers. Interestingly, it is the differentiation through miRNAs and not through the molecular affected pathways that corresponds to the three distinctive categories. Alarming discrepancies among publications were revealed, pertaining to employment of empirical and arbitrary criteria in categorizing the patients. Following bioinformatic analysis, the final step of the current study consisted of a critical analysis of the molecular data sourced, providing a clear and unique insight into the physiological mechanisms involved. It is our intention to contribute to mapping future research dedicated to ovarian insufficiency and to help researchers navigate the overwhelming information published in molecular studies.
PubMed: 33511114
DOI: 10.3389/fcell.2020.590106 -
Sports Medicine (Auckland, N.Z.) Jul 2017Maximal oxygen uptake ([Formula: see text] ) is conventionally normalized to body size as a simple ratio or using an allometric exponent < 1. Nevertheless, the most... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Maximal oxygen uptake ([Formula: see text] ) is conventionally normalized to body size as a simple ratio or using an allometric exponent < 1. Nevertheless, the most appropriate body size variable to use for scaling and the value of the exponent are still enigmatic. Studies tend to be based on small samples and can, therefore, lack precision.
OBJECTIVE
The objective of this systematic review was to provide a quantitative synthesis of reported static allometric exponents used for scaling [Formula: see text] to whole body mass and fat-free mass.
METHODS
Eight electronic databases (CINAHL, Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, PubMed, Scopus, SPORTDiscus and Web of Science) were searched for relevant studies published up to January 2016. Search terms included 'oxygen uptake', 'cardiorespiratory fitness', '[Formula: see text] ', '[Formula: see text] ', 'scaling' and all interchangeable terms. Inclusion criteria included human cardiorespiratory fitness data; cross-sectional study designs; an empirical derivation of the exponent; reported precision statistics; and reported information regarding participant sex, age and sports background, [Formula: see text] protocol, whole body composition protocol and line-fitting methods. A random-effects model was used to quantify weighted pooled exponents and 95% confidence limits (Cls). Heterogeneity was quantified with the tau-statistic (τ). Meta-regression was used to quantify the impact of selected moderator variables on the exponent effect size. A 95% prediction interval was calculated to quantify the likely range of true fat-free mass exponents in similar future studies, with this distribution used to estimate the probability that an exponent would be above theorised universal values of [Formula: see text].
RESULTS
Thirty-six studies, involving 6514 participants, met the eligibility criteria. Whole body mass and fat-free mass were used as the scaling denominator in 27 and 15 studies, respectively. The pooled allometric exponent (95% Cls) was found to be 0.70 (0.64 to 0.76) for whole body mass and 0.90 (0.83 to 0.96) for fat-free mass. The between-study heterogeneity was greater for whole body mass (τ = ±0.15) than for fat-free mass (τ = ±0.11). Participant sex explained 30% of the between-study variability in the whole body mass exponent, but the influence on the fat-free mass exponent was trivial. The whole body mass exponent of 0.52 (0.40 to 0.64) for females was substantially lower than the 0.76 (0.70 to 0.83) for males, whereas the fat-free mass exponent was similar for both sexes. The effects of all other moderators were trivial. The 95% PI for fat-free mass ranged from 0.68 to 1.12. The estimated probability of a true fat-free mass exponent in a future study being greater than [Formula: see text] power scaling is 0.98 (very likely) and 0.92 (likely), respectively.
CONCLUSIONS
In this quantitative synthesis of published studies involving over 6500 humans, the whole body mass exponent was found to be spuriously low and prone to substantial heterogeneity. We conclude that the scaling of [Formula: see text] in humans is consistent with the allometric cascade model with an estimated prediction interval for the fat-free mass exponent not likely to be consistent with the [Formula: see text] power laws.
Topics: Body Composition; Body Size; Female; Humans; Male; Oxygen; Oxygen Consumption
PubMed: 28058696
DOI: 10.1007/s40279-016-0655-1 -
European Journal of Hospital Pharmacy :... Jan 2020Medication error is the most common type of medical error, and intravenous medicines are at a higher risk as they are complex to prepare and administer. The WHO...
OBJECTIVES
Medication error is the most common type of medical error, and intravenous medicines are at a higher risk as they are complex to prepare and administer. The WHO advocates a 50% reduction of harmful medication errors by 2022, but there is a lack of data in the UK that accurately estimates the true rate of intravenous medication errors. This study aimed to estimate the number of intravenous medication errors per 1000 administrations in the UK National Health Service and their associated economic costs. The rate of errors in prescribing, preparation and administration, and rate of different types of errors were also extracted.
METHODS
MEDLINE, Embase, Cochrane central register of clinical trials, Database of Abstracts of Reviews of Effectiveness, National Health Service Economic Evaluation Database and the Health Technology Appraisals Database were searched from inception to July 2017. Epidemiological studies to determine the incidence of intravenous medication errors set wholly or in part in the UK were included. 228 studies were identified, and after screening, eight papers were included, presenting 2576 infusions. Data were reviewed and extracted by a team of five reviewers with discrepancies in data extraction agreed by consensus.
RESULTS
Five of eight studies used a comparable denominator, and these data were pooled to determine a weighted mean incidence of 101 intravenous medication errors per 1000 administrations (95% CI 84 to 121). Three studies presented prevalence data but these were based on spontaneous reports only; therefore it did not support a true estimate. 32.1% (95% CI 30.6% to 33.7%) of intravenous medication errors were administration errors and 'wrong rate' errors accounted for 57.9% (95% CI 54.7% to 61.1%) of these.
CONCLUSION
Intravenous medication errors in the UK are common, with half these of errors related to medication administration. National strategies are aimed at mitigating errors in prescribing and preparation. It is now time to focus on reducing administration error, particularly wrong rate errors.
Topics: Administration, Intravenous; Cost-Benefit Analysis; Humans; Incidence; Medication Errors; Pharmaceutical Preparations; Prevalence; United Kingdom
PubMed: 32064081
DOI: 10.1136/ejhpharm-2018-001624 -
Food Microbiology Apr 2024Enterotoxins produced by Staphylococcus aureus are a common cause of food poisoning, leading to significant gastrointestinal symptoms and even hospitalization. Following... (Review)
Review
Enterotoxins produced by Staphylococcus aureus are a common cause of food poisoning, leading to significant gastrointestinal symptoms and even hospitalization. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched three electronic databases for studies on detection of staphylococcal enterotoxins or enterotoxigenic S. aureus in raw ruminant milk. The 128 studies included in this systematic review showed a worldwide distribution of studies on staphylococcal enterotoxins and enterotoxigenic S. aureus, with an increase in the number from 1980 to 2021, a shift in detection methods from enterotoxins to enterotoxin genes, and a preponderance of studies from Europe and South America. Most studies focused on milk from individual animals with mastitis, especially cattle. Based on 24 studies, the within-herd prevalence of enterotoxigenic S. aureus in raw milk samples was 11.6%. Many studies failed to report the health status of sampled animals, or the numerator and denominator data needed for prevalence calculation. Cultural and legislative differences, economic status, diagnostic capabilities, and public awareness are all likely factors contributing to the observed distribution of studies. Our review highlighted a significant gap in quality and completeness of data reporting, which limits full assessment of prevalence and distribution of hazards posed by raw milk.
Topics: Female; Cattle; Animals; Enterotoxins; Staphylococcus aureus; Milk; Prevalence; Staphylococcal Infections; Ruminants
PubMed: 38049264
DOI: 10.1016/j.fm.2023.104405 -
PloS One 2014About half of medical and health-related studies are not published. We conducted a systematic review of reports on reasons given by investigators for not publishing... (Meta-Analysis)
Meta-Analysis Review
OBJECTIVE
About half of medical and health-related studies are not published. We conducted a systematic review of reports on reasons given by investigators for not publishing their studies in peer-reviewed journals.
METHODS
MEDLINE, EMBASE, PsycINFO, and SCOPUS (until 13/09/2013), and references of identified articles were searched to identify reports of surveys that provided data on reasons given by investigators for not publishing studies. The proportion of non-submission and reasons for non-publication was calculated using the number of unpublished studies as the denominator. Because of heterogeneity across studies, quantitative pooling was not conducted. Exploratory subgroup analyses were conducted.
RESULTS
We included 54 survey reports. Data from 38 included reports were available to estimate proportions of at least one reason given for not publishing studies. The proportion of non-submission among unpublished studies ranged from 55% to 100%, with a median of 85%. The reasons given by investigators for not publishing their studies included: lack of time or low priority (median 33%), studies being incomplete (median 15%), study not for publication (median 14%), manuscript in preparation or under review (median 12%), unimportant or negative result (median 12%), poor study quality or design (median 11%), fear of rejection (median 12%), rejection by journals (median 6%), author or co-author problems (median 10%), and sponsor or funder problems (median 9%). In general, the frequency of reasons given for non-publication was not associated with the source of unpublished studies, study design, or time when a survey was conducted.
CONCLUSIONS
Non-submission of studies for publication remains the main cause of non-publication of studies. Measures to reduce non-publication of studies and alternative models of research dissemination need to be developed to address the main reasons given by investigators for not publishing their studies, such as lack of time or low priority and fear of being rejected by journals.
Topics: Humans; Periodicals as Topic; Publishing; Research Personnel
PubMed: 25335091
DOI: 10.1371/journal.pone.0110418 -
Archivos de Bronconeumologia Jan 2012Post-thoracotomy pain is a symptom of high incidence among patients who have undergone thoracotomy and is a major risk factor in the pathogenesis of several... (Review)
Review
Post-thoracotomy pain is a symptom of high incidence among patients who have undergone thoracotomy and is a major risk factor in the pathogenesis of several postoperative complications. Chronic pain after thoracotomy reaches a high prevalence. Since the earliest studies, this pain has been seen to be related with intercostal nerve injury, thus the need to avoid these lesions during thoracotomy has been recommended. This review aims to establish the appropriate surgical procedure for closure of the thoracotomy through a systematic review of the literature and analysis of levels of evidence provided by the studies found. After an exhaustive search in MEDLINE, EMBASE, IME, IBECS and Cochrane Library, few studies were found. Each focuses on different aspects of thoracotomy surgical techniques, with a common denominator focused on the preservation of the intercostal nerves, and conclusions with different levels of evidence.
Topics: Absorbable Implants; Chest Pain; Cohort Studies; Humans; Incidence; Intercostal Nerves; Intraoperative Complications; Pain, Postoperative; Pneumonectomy; Prevalence; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Surgical Flaps; Suture Techniques; Thoracotomy; Wound Closure Techniques
PubMed: 22019365
DOI: 10.1016/j.arbres.2011.04.012 -
Lancet (London, England) Apr 2015Aggregate and risk-stratified perioperative mortality rates (POMR) are well-documented in high-income countries where surgical databases are common. In many low-income...
BACKGROUND
Aggregate and risk-stratified perioperative mortality rates (POMR) are well-documented in high-income countries where surgical databases are common. In many low-income and middle-income country (LMIC) settings, such data are unavailable, compromising efforts to understand and improve surgical outcomes. We undertook a systematic review to determine how POMR is used and defined in LMICs and to inform baseline rates.
METHODS
We searched PubMed for all articles published between Jan 1, 2009, and Sept 1, 2014, reporting surgical mortality in LMICs. Search criteria, inclusion and exclusion criteria, and study assessment methodology are reported in the appendix. Titles and abstracts were screened independently by two reviewers. Full-text review and data extraction were completed by four trained clinician coders with regular validation for consistency. We extracted the definition of POMR used, clinical risk scores reported, and strategies for risk adjustment in addition to reported mortality rates.
FINDINGS
We screened 2657 abstracts and included 373 full-text articles. 493 409 patients in 68 countries and 12 surgical specialties were represented. The most common definition for the numerator of POMR was in-hospital deaths following surgery (55·3%) and for the denominator it was the number of operative patients (96·2%). Few studies reported preoperative comorbidities (41·8%), ASA status (11·3%), and HIV status (7·8%), with a smaller proportion stratifying on or adjusting mortality for these factors. Studies reporting on planned procedures recorded a median mortality of 1·2% (n=121 [IQR 0·0-4·7]). Median mortality was 10·1% (n=182 [IQR 2·5-16·2) for emergent procedures.
INTERPRETATION
POMR is frequently reported in LMICs, but a standardised approach for reporting and risk stratification is absent from the literature. There was wide variation in POMR across procedures and specialties. A quality assessment checklist for surgical mortality studies could improve mortality reporting and facilitate benchmarking across sites and countries.
FUNDING
None.
PubMed: 26313076
DOI: 10.1016/S0140-6736(15)60824-8 -
Euro Surveillance : Bulletin Europeen... Feb 2024BackgroundThere is currently no standardised approach to estimate respiratory syncytial virus (RSV) epidemics' timing (or seasonality), a critical information for their...
BackgroundThere is currently no standardised approach to estimate respiratory syncytial virus (RSV) epidemics' timing (or seasonality), a critical information for their effective prevention and control.AimWe aimed to provide an overview of methods to define RSV seasonality and identify factors supporting method choice or interpretation/comparison of seasonal estimates.MethodsWe systematically searched PubMed and Embase (2016-2021) for studies using quantitative approaches to determine the start and end of RSV epidemics. Studies' features (data-collection purpose, location, regional/(sub)national scope), methods, and assessment characteristics (case definitions, sampled population's age, in/outpatient status, setting, diagnostics) were extracted. Methods were categorised by their need of a denominator (i.e. numbers of specimens tested) and their retrospective vs real-time application. Factors worth considering when choosing methods and assessing seasonal estimates were sought by analysing studies.ResultsWe included 32 articles presenting 49 seasonality estimates (18 thereof through the 10% positivity threshold method). Methods were classified into eight categories, two requiring a denominator (1 retrospective; 1 real-time) and six not (3 retrospective; 3 real-time). A wide range of assessment characteristics was observed. Several studies showed that seasonality estimates varied when methods differed, or data with dissimilar assessment characteristics were employed. Five factors (comprising study purpose, application time, assessment characteristics, healthcare system and policies, and context) were identified that could support method choice and result interpretation.ConclusionMethods and assessment characteristics used to define RSV seasonality are heterogeneous. Our categorisation of methods and proposed framework of factors may assist in choosing RSV seasonality methods and interpretating results.
Topics: Humans; Infant; Respiratory Syncytial Virus Infections; Retrospective Studies; Seasons; Respiratory Syncytial Virus, Human; Epidemics
PubMed: 38304952
DOI: 10.2807/1560-7917.ES.2024.29.5.2300244 -
BMJ (Clinical Research Ed.) May 2003To systematically review measures of data quality in electronic patient records (EPRs) in primary care. (Review)
Review
OBJECTIVE
To systematically review measures of data quality in electronic patient records (EPRs) in primary care.
DESIGN
Systematic review of English language publications, 1980-2001.
DATA SOURCES
Bibliographic searches of medical databases, specialist medical informatics databases, conference proceedings, and institutional contacts.
STUDY SELECTION
Studies selected according to a predefined framework for categorising review papers.
DATA EXTRACTION
Reference standards and measurements used to judge quality.
RESULTS
Bibliographic searches identified 4589 publications. After primary exclusions 174 articles were classified, 52 of which met the inclusion criteria for review. Selected studies were primarily descriptive surveys. Variability in methods prevented meta-analysis of results. Forty eight publications were concerned with diagnostic data, 37 studies measured data quality, and 15 scoped EPR quality. Reliability of data was assessed with rate comparison. Measures of sensitivity were highly dependent on the element of EPR data being investigated, while the positive predictive value was consistently high, indicating good validity. Prescribing data were generally of better quality than diagnostic or lifestyle data.
CONCLUSION
The lack of standardised methods for assessment of quality of data in electronic patient records makes it difficult to compare results between studies. Studies should present data quality measures with clear numerators, denominators, and confidence intervals. Ambiguous terms such as "accuracy" should be avoided unless precisely defined.
Topics: Ambulatory Care Information Systems; Data Collection; Humans; Medical Records Systems, Computerized; Primary Health Care; Quality of Health Care; Reproducibility of Results; State Medicine; United Kingdom
PubMed: 12750210
DOI: 10.1136/bmj.326.7398.1070